1. Generics Bulletin
  2. >>Market Intelligence
  3. >>Company Rankings

The Generics Bulletin Top 50, Part Two: Mid-Table Movements See Firms Jostle For Position

Some Companies Climb As Others Slip Down Rankings

 
• By Dave Wallace

Medium-sized generics and biosimilars players have seen ups and downs over the past year, with some changes to the order of these mid-table players seen as we continue to work our way through Generics Bulletin’s annual Top 50.

Generics Bulletin Top 50 2022
Mid-table companies have moved in various directions • Source: Shutterstock

With the significant movements seen among the 10 leading companies in Generics Bulletin’s Top 50 this year nevertheless leaving the ranking order of firms at the very top of that top-10 table undisturbed, a similar trend can be observed in the second part of our rundown, covering positions 11-30. (Also see "The Generics Bulletin Top 50, Part One: Industry Top 10 Reshaped By Leaders’ Transformations" - Generics Bulletin, 15 August, 2022.)

Compared to last year, the same five companies lead off this second table, in the same order – with Cipla,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Company Rankings

Generics Bulletin’s Top 50 Ranking For 2024

 
• By Dave Wallace

This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.

The Generics Bulletin Top 50, Part Three: Firms Fall Out Of Final Grouping

 
• By Dave Wallace

In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.

The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players

 
• By Dave Wallace

In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.

The Generics Bulletin Top 50, Part One: Top Ten Ranking Conceals Changes For Industry Leaders

 
• By Dave Wallace

A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.

More from Market Intelligence

Trihexyphenidyl Tablets Treble In A Busy March For UK Price Rises

 
• By Dave Wallace

Trihexyphenidyl tablets in two different strengths led a raft of UK generic price rises in March, according to the latest figures from WaveData.

Trimethoprim Trebles As Last Month’s UK Fallers Bounce Back

 
• By Dave Wallace

In a month that saw the average prices of five generic presentations more than double in the UK, WaveData’s figures showed trimethoprim leading the rises with an enormous price increase in February, as several products bounced back from declines in the previous month.

Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm

 
• By Dave Wallace

Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.